Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.
Also called NCT02453555
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 275 participants
- Registry
-
NCT02453555
-
- Other papers using this trial's data
- Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02453555. Randomized; double masking; primary purpose treatment. Start 2015-05-14 (actual); primary completion 2016-08-26 (actual). Results posted on 2019-02-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Empagliflozin placebo + linagliptin placebo low dose
- Intervention (Drug)
- Empagliflozin + linagliptin low dose
- Intervention (Drug)
- Linagliptin placebo
- Intervention (Drug)
- Empagliflozin + linagliptin high dose
- Intervention (Drug)
- Empa + lina highdose placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02453555- Content hash
20e02a321d8e1ca436871e79c1867a77271320e401cff77b1b76e27a269e0b69